2,000 Miniature Disposable Insulin Pump Units

Executives from Andain Inc., a company engaged in commercializing novel technologies in the fields of biotech, medical, and life sciences through its accelerating incubator program, announce the production of 2,000 miniature disposable insulin pump units for clinical trials.

The diabetes management products market, including insulin injection devices and insulin pumps, insulin therapies and oral and injectable diabetes drugs-have become one of the largest medical device markets in the U.S. totaling more than $20 billion in 2008. The insulin pump market is sizeable and rapidly growing. Global markets sales are estimated to be more than $1 billion annually with a 12% compound annual growth rate.

Andain's technological industrial accelerating incubator, has assembled 2,000 units of its miniature disposable insulin pump for type-I and type-II diabetes to be used in forthcoming clinical trials.  

Although the planned clinical trials are not required for FDA approval, Andain is about to conduct a comprehensive clinical trial intended for type-II diabetes, aiming to show significant clinical and ease-of-use advantages utilizing the company's miniature disposable pump, intended to replace the common pen injector with similar cost to the patient or medical insurer.

Andain's miniature disposable insulin pump is an ultra slim, low profile, small Band-Aid patch-size, fully disposable, fully programmable, water-proof, low cost insulin pump. Along with the plug-in universal remote-control (PUR) unit capable of interfacing with any smartphone, hand-held, laptop, or desk-top computer, it provides one of the safest, most comfortable and yet affordable clinically superior solution for the type-II diabetes community.

"Our current initial production line, enables us to continue developing and assimilating methodologies to be used on a large scale production base, and further reduce production costs," says Andain President & CEO, Sam Elimelech.